Nanjing Vazyme Biotech Co Ltd (SHG:688105) — Market Cap & Net Worth
Market Cap & Net Worth: Nanjing Vazyme Biotech Co Ltd (688105)
Nanjing Vazyme Biotech Co Ltd (SHG:688105) has a market capitalization of $914.92 Million (CN¥6.25 Billion) as of June 23, 2026. Listed on the SHG stock exchange, this China-based company holds position #9449 globally and #2461 in its home market, demonstrating a 15.50% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nanjing Vazyme Biotech Co Ltd's stock price CN¥15.72 by its total outstanding shares 397734544 (397.73 Million). Review Nanjing Vazyme Biotech Co Ltd total liabilities to assess the company's total debt and financial obligations.
Nanjing Vazyme Biotech Co Ltd Market Cap History: 2021 to 2026
Nanjing Vazyme Biotech Co Ltd's market capitalization history from 2021 to 2026. Data shows change from $5.88 Billion to $914.92 Million (-30.10% CAGR).
Nanjing Vazyme Biotech Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nanjing Vazyme Biotech Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.85x
Nanjing Vazyme Biotech Co Ltd's market cap is 0.85 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $5.88 Billion | $1.87 Billion | $678.29 Million | 3.15x | 8.67x |
| 2022 | $2.96 Billion | $3.57 Billion | $594.25 Million | 0.83x | 4.98x |
| 2023 | $1.85 Billion | $1.29 Billion | -$70.96 Million | 1.44x | N/A |
| 2024 | $1.29 Billion | $1.38 Billion | -$18.09 Million | 0.94x | N/A |
| 2025 | $1.17 Billion | $1.38 Billion | -$16.97 Million | 0.85x | N/A |
Competitor Companies of 688105 by Market Capitalization
Companies near Nanjing Vazyme Biotech Co Ltd in the global market cap rankings as of June 23, 2026.
Key companies related to Nanjing Vazyme Biotech Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
Nanjing Vazyme Biotech Co Ltd Historical Marketcap From 2021 to 2026
Between 2021 and today, Nanjing Vazyme Biotech Co Ltd's market cap moved from $5.88 Billion to $ 914.92 Million, with a yearly change of -30.10%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥914.92 Million | -21.48% |
| 2025 | CN¥1.17 Billion | -9.70% |
| 2024 | CN¥1.29 Billion | -30.38% |
| 2023 | CN¥1.85 Billion | -37.38% |
| 2022 | CN¥2.96 Billion | -49.68% |
| 2021 | CN¥5.88 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 22nd, 2026 the market cap of Nanjing Vazyme Biotech Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $914.92 Million USD |
| MoneyControl | $914.92 Million USD |
| MarketWatch | $914.92 Million USD |
| marketcap.company | $914.92 Million USD |
| Reuters | $914.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nanjing Vazyme Biotech Co Ltd
Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real… Read more